{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T17:02:33Z","timestamp":1791392553708,"version":"4.3.3"},"reference-count":89,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T00:00:00Z","timestamp":1753056000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T00:00:00Z","timestamp":1753056000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Astra Zeneca, Abbott Technologies, and Boston Scientific","award":["speaker\u2019s fees and research grants"],"award-info":[{"award-number":["speaker\u2019s fees and research grants"]}]},{"name":"NUHS Seed Fund","award":["NUHSRO\/2022\/058\/RO5+6\/Seed-Mar\/03"],"award-info":[{"award-number":["NUHSRO\/2022\/058\/RO5+6\/Seed-Mar\/03"]}]},{"name":"National Medical Research Council Research Training Fellowship","award":["MH 095:003\/008-303"],"award-info":[{"award-number":["MH 095:003\/008-303"]}]},{"name":"National University of Singapore Yong Loo Lin School of Medicine\u2019s Academic Fellowship Scheme, and the NUHS Clinician Scientist Program","award":["NCSP2.0\/2024\/NUHS\/NCWS"],"award-info":[{"award-number":["NCSP2.0\/2024\/NUHS\/NCWS"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-12583-6","type":"journal-article","created":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T20:43:36Z","timestamp":1753130616000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Non-invasive scoring systems of liver fibrosis predict prognosis in the cohort with myocardial infarction"],"prefix":"10.1038","volume":"15","author":[{"given":"Esther","family":"Wong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiming","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gwyneth","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jobelle","family":"Chia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anurag","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayanth","family":"Jayabaskaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan","family":"Chong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Nah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark Yan-Yee","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Muthiah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Poay-Huan","family":"Loh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamas A.","family":"Mamas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0640-0430","authenticated-orcid":false,"given":"Nicholas WS","family":"Chew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,21]]},"reference":[{"key":"12583_CR1","doi-asserted-by":"publisher","first-page":"11","DOI":"10.5334\/gh.1288","volume":"19","author":"M Di Cesare","year":"2024","unstructured":"Di Cesare, M. et al. The heart of the world. Glob Heart. 19, 11. https:\/\/doi.org\/10.5334\/gh.1288 (2024).","journal-title":"Glob Heart"},{"key":"12583_CR2","doi-asserted-by":"publisher","unstructured":"Gutierrez-Cuevas, J., Santos, A. & Armendariz-Borunda, J. Pathophysiological molecular mechanisms of obesity: A link between MAFLD and NASH with cardiovascular diseases. Int. J. Mol. Sci. 22 https:\/\/doi.org\/10.3390\/ijms222111629 (2021).","DOI":"10.3390\/ijms222111629"},{"key":"12583_CR3","doi-asserted-by":"publisher","first-page":"100803","DOI":"10.1016\/j.lanwpc.2023.100803","volume":"37","author":"NWS Chew","year":"2023","unstructured":"Chew, N. W. S. et al. Trends and predictions of metabolic risk factors for acute myocardial infarction: findings from a multiethnic nationwide cohort. Lancet Reg. Health West. Pac. 37, 100803. https:\/\/doi.org\/10.1016\/j.lanwpc.2023.100803 (2023).","journal-title":"Lancet Reg. Health West. Pac."},{"key":"12583_CR4","doi-asserted-by":"publisher","first-page":"101138","DOI":"10.1016\/j.lanwpc.2024.101138","volume":"49","author":"RSJ Goh","year":"2024","unstructured":"Goh, R. S. J. et al. The burden of cardiovascular disease in Asia from 2025 to 2050: a forecast analysis for East asia, South asia, South-East asia, central asia, and high-income Asia Pacific regions. Lancet Reg. Health West. Pac. 49, 101138. https:\/\/doi.org\/10.1016\/j.lanwpc.2024.101138 (2024).","journal-title":"Lancet Reg. Health West. Pac."},{"key":"12583_CR5","doi-asserted-by":"publisher","DOI":"10.1093\/eurjpc\/zwae281","author":"B Chong","year":"2024","unstructured":"Chong, B. et al. Global burden of cardiovascular diseases: projections from 2025 to 2050. Eur. J. Prev. Cardiol. https:\/\/doi.org\/10.1093\/eurjpc\/zwae281 (2024).","journal-title":"Eur. J. Prev. Cardiol."},{"key":"12583_CR6","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1136\/hrt.2008.144022","volume":"95","author":"CP Gale","year":"2009","unstructured":"Gale, C. P. et al. Evaluation of risk scores for risk stratification of acute coronary syndromes in the myocardial infarction National audit project (MINAP) database. Heart 95, 221\u2013227. https:\/\/doi.org\/10.1136\/hrt.2008.144022 (2009).","journal-title":"Heart"},{"key":"12583_CR7","doi-asserted-by":"publisher","first-page":"e073843","DOI":"10.1136\/bmj-2022-073843","volume":"381","author":"CP Gale","year":"2023","unstructured":"Gale, C. P. et al. Effectiveness of GRACE risk score in patients admitted to hospital with non-ST elevation acute coronary syndrome (UKGRIS): parallel group cluster randomised controlled trial. BMJ 381, e073843. https:\/\/doi.org\/10.1136\/bmj-2022-073843 (2023).","journal-title":"BMJ"},{"key":"12583_CR8","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1016\/j.jacc.2023.06.045","volume":"82","author":"GA Figtree","year":"2023","unstructured":"Figtree, G. A. et al. Clinical pathway for coronary atherosclerosis in patients without conventional modifiable risk factors: JACC State-of-the-Art review. J. Am. Coll. Cardiol. 82, 1343\u20131359. https:\/\/doi.org\/10.1016\/j.jacc.2023.06.045 (2023).","journal-title":"J. Am. Coll. Cardiol."},{"key":"12583_CR9","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1056\/NEJMoa2029349","volume":"385","author":"AJ Sanyal","year":"2021","unstructured":"Sanyal, A. J. et al. Prospective study of outcomes in adults with nonalcoholic fatty liver disease. N Engl. J. Med. 385, 1559\u20131569. https:\/\/doi.org\/10.1056\/NEJMoa2029349 (2021).","journal-title":"N Engl. J. Med."},{"key":"12583_CR10","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.eprac.2022.10.007","volume":"29","author":"CE Fu","year":"2023","unstructured":"Fu, C. E. et al. A Meta-analysis on associated risk of mortality in nonalcoholic fatty liver disease. Endocr. Pract. 29, 33\u201339. https:\/\/doi.org\/10.1016\/j.eprac.2022.10.007 (2023).","journal-title":"Endocr. Pract."},{"key":"12583_CR11","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1111\/apt.17397","volume":"57","author":"CE Fu","year":"2023","unstructured":"Fu, C. E. et al. The prognostic value of including non-alcoholic fatty liver disease in the definition of metabolic syndrome. Aliment. Pharmacol. Ther. 57, 979\u2013987. https:\/\/doi.org\/10.1111\/apt.17397 (2023).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"12583_CR12","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15660","author":"G Kong","year":"2024","unstructured":"Kong, G. et al. The prognostic value of metabolic dysfunction-associated steatotic liver disease in acute myocardial infarction: A propensity score-matched analysis. Diabetes Obes. Metab. https:\/\/doi.org\/10.1111\/dom.15660 (2024).","journal-title":"Diabetes Obes. Metab."},{"key":"12583_CR13","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1111\/dom.14950","volume":"25","author":"Y Chin","year":"2023","unstructured":"Chin, Y. et al. Hepatic steatosis and advanced hepatic fibrosis are independent predictors of long-term mortality in acute myocardial infarction. Diabetes Obes. Metab. 25, 1032\u20131044. https:\/\/doi.org\/10.1111\/dom.14950 (2023).","journal-title":"Diabetes Obes. Metab."},{"key":"12583_CR14","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s12933-024-02552-0","volume":"24","author":"G Kong","year":"2025","unstructured":"Kong, G. et al. A sex-disaggregated analysis of the prognostic value of lean type 2 diabetes mellitus in the adult population with acute myocardial infarction. Cardiovasc. Diabetol. 24, 59. https:\/\/doi.org\/10.1186\/s12933-024-02552-0 (2025).","journal-title":"Cardiovasc. Diabetol."},{"key":"12583_CR15","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJM200102153440706","volume":"344","author":"AA Bravo","year":"2001","unstructured":"Bravo, A. A., Sheth, S. G. & Chopra, S. Liver biopsy. N Engl. J. Med. 344, 495\u2013500. https:\/\/doi.org\/10.1056\/NEJM200102153440706 (2001).","journal-title":"N Engl. J. Med."},{"key":"12583_CR16","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1053\/j.gastro.2005.03.084","volume":"128","author":"V Ratziu","year":"2005","unstructured":"Ratziu, V. et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 128, 1898\u20131906. https:\/\/doi.org\/10.1053\/j.gastro.2005.03.084 (2005).","journal-title":"Gastroenterology"},{"key":"12583_CR17","doi-asserted-by":"publisher","first-page":"7427","DOI":"10.3748\/wjg.v21.i24.7427","volume":"21","author":"H Enomoto","year":"2015","unstructured":"Enomoto, H., Bando, Y., Nakamura, H., Nishiguchi, S. & Koga, M. Liver fibrosis markers of nonalcoholic steatohepatitis. World J. Gastroenterol. 21, 7427\u20137435. https:\/\/doi.org\/10.3748\/wjg.v21.i24.7427 (2015).","journal-title":"World J. Gastroenterol."},{"key":"12583_CR18","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1016\/j.jacc.2018.11.050","volume":"73","author":"EP Stahl","year":"2019","unstructured":"Stahl, E. P. et al. Nonalcoholic fatty liver disease and the heart: JACC State-of-the-Art review. J. Am. Coll. Cardiol. 73, 948\u2013963. https:\/\/doi.org\/10.1016\/j.jacc.2018.11.050 (2019).","journal-title":"J. Am. Coll. Cardiol."},{"key":"12583_CR19","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1161\/CIRCULATIONAHA.124.070535","volume":"151","author":"NWS Chew","year":"2025","unstructured":"Chew, N. W. S. et al. Cardiovascular-Liver-Metabolic health: recommendations in screening, diagnosis, and management of metabolic Dysfunction-Associated steatotic liver disease in cardiovascular disease via modified Delphi approach. Circulation 151, 98\u2013119. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.124.070535 (2025).","journal-title":"Circulation"},{"key":"12583_CR20","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s12072-022-10319-6","volume":"16","author":"JN Yong","year":"2022","unstructured":"Yong, J. N. et al. Non-alcoholic fatty liver disease association with structural heart, systolic and diastolic dysfunction: a meta-analysis. Hepatol. Int. 16, 269\u2013281. https:\/\/doi.org\/10.1007\/s12072-022-10319-6 (2022).","journal-title":"Hepatol. Int."},{"key":"12583_CR21","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s12902-022-00980-1","volume":"22","author":"S Pouwels","year":"2022","unstructured":"Pouwels, S. et al. Non-alcoholic fatty liver disease (NAFLD): a review of pathophysiology, clinical management and effects of weight loss. BMC Endocr. Disord. 22, 63. https:\/\/doi.org\/10.1186\/s12902-022-00980-1 (2022).","journal-title":"BMC Endocr. Disord"},{"key":"12583_CR22","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1111\/dom.16062","volume":"27","author":"J Koh","year":"2025","unstructured":"Koh, J. et al. Long-term all-cause mortality of metabolic-dysfunction associated steatotic liver disease based on body weight phenotypes following acute myocardial infarction: A retrospective cohort study. Diabetes Obes. Metab. 27, 683\u2013696. https:\/\/doi.org\/10.1111\/dom.16062 (2025).","journal-title":"Diabetes Obes. Metab."},{"key":"12583_CR23","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1016\/j.cjca.2022.07.016","volume":"38","author":"NWS Chew","year":"2022","unstructured":"Chew, N. W. S. et al. FIB-4 predicts MACE and cardiovascular mortality in patients with nonalcoholic fatty liver disease. Can. J. Cardiol. 38, 1779\u20131780. https:\/\/doi.org\/10.1016\/j.cjca.2022.07.016 (2022).","journal-title":"Can. J. Cardiol."},{"key":"12583_CR24","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000913","author":"X Qi","year":"2024","unstructured":"Qi, X., Li, J., Caussy, C., Teng, G. J. & Loomba, R. Epidemiology, screening, and co-management of type 2 diabetes mellitus and metabolic dysfunction-associated steatotic liver disease. Hepatology https:\/\/doi.org\/10.1097\/HEP.0000000000000913 (2024).","journal-title":"Hepatology"},{"key":"12583_CR25","doi-asserted-by":"publisher","first-page":"100762","DOI":"10.1016\/j.aohep.2022.100762","volume":"28","author":"M Muthiah","year":"2023","unstructured":"Muthiah, M. et al. Type 2 diabetes mellitus in metabolic-associated fatty liver disease vs. type 2 diabetes mellitus non-alcoholic fatty liver disease: a longitudinal cohort analysis. Ann. Hepatol. 28, 100762. https:\/\/doi.org\/10.1016\/j.aohep.2022.100762 (2023).","journal-title":"Ann. Hepatol."},{"key":"12583_CR26","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/s41366-023-01429-8","volume":"48","author":"MTW Kueh","year":"2024","unstructured":"Kueh, M. T. W., Chew, N. W. S., Al-Ozairi, E. & le Roux, C. W. The emergence of obesity in type 1 diabetes. Int. J. Obes. (Lond). 48, 289\u2013301. https:\/\/doi.org\/10.1038\/s41366-023-01429-8 (2024).","journal-title":"Int. J. Obes. (Lond)"},{"key":"12583_CR27","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1093\/eurjpc\/zwad133","volume":"30","author":"CYL Yaow","year":"2023","unstructured":"Yaow, C. Y. L. et al. Higher risk of adverse cardiovascular outcomes in females with type 2 diabetes mellitus: an umbrella review of systematic reviews. Eur. J. Prev. Cardiol. 30, 1227\u20131235. https:\/\/doi.org\/10.1093\/eurjpc\/zwad133 (2023).","journal-title":"Eur. J. Prev. Cardiol."},{"key":"12583_CR28","doi-asserted-by":"publisher","unstructured":"Chan, K. E. et al. Longitudinal Outcomes Associated With Metabolic Dysfunction-Associated Steatotic Liver Disease: A Meta-analysis of 129 Studies. Clin. Gastroenterol. Hepatol. 22, 488\u2013498 e414 (2024). https:\/\/doi.org\/10.1016\/j.cgh.2023.09.018","DOI":"10.1016\/j.cgh.2023.09.018"},{"key":"12583_CR29","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s11886-024-02025-6","volume":"26","author":"ECZ Lee","year":"2024","unstructured":"Lee, E. C. Z. et al. The global epidemic of metabolic fatty liver disease. Curr. Cardiol. Rep. 26, 199\u2013210. https:\/\/doi.org\/10.1007\/s11886-024-02025-6 (2024).","journal-title":"Curr. Cardiol. Rep."},{"key":"12583_CR30","doi-asserted-by":"publisher","first-page":"1193829","DOI":"10.3389\/fmed.2023.1193829","volume":"10","author":"VV Anand","year":"2023","unstructured":"Anand, V. V. et al. General public\u2019s knowledge, awareness, and perception of cardiometabolic diseases: data from a Singapore study population. Front. Med. (Lausanne). 10, 1193829. https:\/\/doi.org\/10.3389\/fmed.2023.1193829 (2023).","journal-title":"Front. Med. (Lausanne)"},{"key":"12583_CR31","doi-asserted-by":"publisher","unstructured":"Chin, Y., Lim, J. & Kong, G. & et.al. Hepatic steatosis and advanced hepatic fibrosis are independent predictors of long-term mortality in acute myocardial infarction. Diabetes Obes. Metab 25, 1032\u20131044 https:\/\/doi.org\/10.1111\/dom.14950","DOI":"10.1111\/dom.14950"},{"key":"12583_CR32","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/S1665-2681(19)31836-8","volume":"7","author":"A Loaeza-del-Castillo","year":"2008","unstructured":"Loaeza-del-Castillo, A., Paz-Pineda, F., Oviedo-Cardenas, E., Sanchez-Avila, F. & Vargas-Vorackova, F. AST to platelet ratio index (APRI) for the noninvasive evaluation of liver fibrosis. Ann. Hepatol. 7, 350\u2013357 (2008).","journal-title":"Ann. Hepatol."},{"key":"12583_CR33","doi-asserted-by":"publisher","unstructured":"European Association for the Study of the Liver. Electronic address, e. e. e., Clinical Practice Guideline & Chair, P. representative, E. G. B. & Panel, m. EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis \u2013\u20092021 update. J. Hepatol. 75, 659\u2013689 (2021). https:\/\/doi.org\/10.1016\/j.jhep.2021.05.025","DOI":"10.1016\/j.jhep.2021.05.025"},{"key":"12583_CR34","doi-asserted-by":"publisher","unstructured":"Thygesen, K. et al. Fourth Universal Definition of Myocardial Infarction Circulation 138, e618-e651 (2018). (2018). https:\/\/doi.org\/10.1161\/CIR.0000000000000617","DOI":"10.1161\/CIR.0000000000000617"},{"key":"12583_CR35","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.amjcard.2022.02.044","volume":"173","author":"NWS Chew","year":"2022","unstructured":"Chew, N. W. S. et al. Meta-Analysis of percutaneous coronary intervention versus coronary artery bypass grafting for left main narrowing. Am. J. Cardiol. 173, 39\u201347. https:\/\/doi.org\/10.1016\/j.amjcard.2022.02.044 (2022).","journal-title":"Am. J. Cardiol."},{"key":"12583_CR36","doi-asserted-by":"publisher","first-page":"822228","DOI":"10.3389\/fcvm.2022.822228","volume":"9","author":"NWS Chew","year":"2022","unstructured":"Chew, N. W. S. et al. Coronary artery bypass grafting versus percutaneous coronary intervention for multivessel coronary artery disease: A One-Stage Meta-Analysis. Front. Cardiovasc. Med. 9, 822228. https:\/\/doi.org\/10.3389\/fcvm.2022.822228 (2022).","journal-title":"Front. Cardiovasc. Med."},{"key":"12583_CR37","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1002\/hep.21178","volume":"43","author":"RK Sterling","year":"2006","unstructured":"Sterling, R. K. et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection. Hepatology 43, 1317\u20131325. https:\/\/doi.org\/10.1002\/hep.21178 (2006).","journal-title":"Hepatology"},{"key":"12583_CR38","doi-asserted-by":"publisher","first-page":"110206","DOI":"10.1016\/j.diabres.2022.110206","volume":"195","author":"J Song","year":"2023","unstructured":"Song, J. et al. Fibrosis-4 stage of liver fibrosis predicts cardiovascular outcomes in acute coronary syndrome patients with and without type 2 diabetes mellitus. Diabetes Res. Clin. Pract. 195, 110206. https:\/\/doi.org\/10.1016\/j.diabres.2022.110206 (2023).","journal-title":"Diabetes Res. Clin. Pract."},{"key":"12583_CR39","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1016\/j.cgh.2009.05.033","volume":"7","author":"AG Shah","year":"2009","unstructured":"Shah, A. G. et al. Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin. Gastroenterol. Hepatol. 7, 1104\u20131112. https:\/\/doi.org\/10.1016\/j.cgh.2009.05.033 (2009).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"12583_CR40","doi-asserted-by":"crossref","unstructured":"Liver, E. A. & Obesity, E. A. f. t. S. o. t., Diabetes, E. A. f. t. S. o. f. t. S. o. EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). Obesity Facts 17, 374\u2013443 (2024).","DOI":"10.1159\/000539371"},{"key":"12583_CR41","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","volume":"77","author":"ME Rinella","year":"2023","unstructured":"Rinella, M. E. et al. AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology 77, 1797\u20131835 (2023).","journal-title":"Hepatology"},{"key":"12583_CR42","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1053\/jhep.2003.50346","volume":"38","author":"C Wai","year":"2003","unstructured":"Wai, C. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 38, 518\u2013526. https:\/\/doi.org\/10.1053\/jhep.2003.50346 (2003).","journal-title":"Hepatology"},{"key":"12583_CR43","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1002\/jgh3.12219","volume":"4","author":"P Sripongpun","year":"2020","unstructured":"Sripongpun, P. et al. Evaluation of aspartate aminotransferase to platelet ratio index and fibrosis 4 scores for hepatic fibrosis assessment compared with transient elastography in chronic hepatitis C patients. JGH Open. 4, 69\u201374. https:\/\/doi.org\/10.1002\/jgh3.12219 (2020).","journal-title":"JGH Open."},{"key":"12583_CR44","unstructured":"J, M. & Zaj\u0105c Nafld fibrosis score calculator, https:\/\/www.omnicalculator.com\/health\/nafld-fibrosis-score (."},{"key":"12583_CR45","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1002\/hep.21496","volume":"45","author":"P Angulo","year":"2007","unstructured":"Angulo, P. et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 45, 846\u2013854. https:\/\/doi.org\/10.1002\/hep.21496 (2007).","journal-title":"Hepatology"},{"key":"12583_CR46","doi-asserted-by":"publisher","first-page":"869168","DOI":"10.3389\/fcvm.2022.869168","volume":"9","author":"G Kong","year":"2022","unstructured":"Kong, G. et al. Prognostic outcomes in acute myocardial infarction patients without standard modifiable risk factors: A multiethnic study of 8,680 Asian patients. Front. Cardiovasc. Med. 9, 869168. https:\/\/doi.org\/10.3389\/fcvm.2022.869168 (2022).","journal-title":"Front. Cardiovasc. Med."},{"key":"12583_CR47","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1016\/j.eprac.2022.05.007","volume":"28","author":"NWS Chew","year":"2022","unstructured":"Chew, N. W. S. et al. Long-Term prognosis of acute myocardial infarction associated with metabolic health and obesity status. Endocr. Pract. 28, 802\u2013810. https:\/\/doi.org\/10.1016\/j.eprac.2022.05.007 (2022).","journal-title":"Endocr. Pract."},{"key":"12583_CR48","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1016\/j.cjca.2022.03.010","volume":"38","author":"NWS Chew","year":"2022","unstructured":"Chew, N. W. S. et al. Long-term prognosis in patients with concomitant acute coronary syndrome and aortic stenosis. Can. J. Cardiol. 38, 1220\u20131227. https:\/\/doi.org\/10.1016\/j.cjca.2022.03.010 (2022).","journal-title":"Can. J. Cardiol."},{"key":"12583_CR49","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1007\/s11239-022-02704-7","volume":"54","author":"G Kong","year":"2022","unstructured":"Kong, G. et al. Long-term outcomes in acute coronary syndrome patients without standard modifiable risk factors: a multi-ethnic retrospective cohort study of 5400 Asian patients. J. Thromb. Thrombolysis. 54, 569\u2013578. https:\/\/doi.org\/10.1007\/s11239-022-02704-7 (2022).","journal-title":"J. Thromb. Thrombolysis"},{"key":"12583_CR50","doi-asserted-by":"publisher","first-page":"e009340","DOI":"10.1161\/CIRCOUTCOMES.122.009340","volume":"16","author":"G Kong","year":"2023","unstructured":"Kong, G. et al. Long-Term prognosis of patients with coexisting obesity and malnutrition after acute myocardial infarction: A cohort study. Circ. Cardiovasc. Qual. Outcomes. 16, e009340. https:\/\/doi.org\/10.1161\/CIRCOUTCOMES.122.009340 (2023).","journal-title":"Circ. Cardiovasc. Qual. Outcomes"},{"key":"12583_CR51","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.jhep.2017.09.021","volume":"68","author":"A Lonardo","year":"2018","unstructured":"Lonardo, A., Nascimbeni, F., Mantovani, A. & Targher, G. Hypertension, diabetes, atherosclerosis and NASH: cause or consequence? J. Hepatol. 68, 335\u2013352. https:\/\/doi.org\/10.1016\/j.jhep.2017.09.021 (2018).","journal-title":"J. Hepatol."},{"key":"12583_CR52","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1111\/apt.17121","volume":"56","author":"CH Ng","year":"2022","unstructured":"Ng, C. H. et al. Living in the non-alcoholic fatty liver disease silent epidemic: a qualitative systematic review of patients\u2019 perspectives. Aliment. Pharmacol. Ther. 56, 570\u2013579. https:\/\/doi.org\/10.1111\/apt.17121 (2022).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"12583_CR53","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1002\/oby.23658","volume":"31","author":"G Kong","year":"2023","unstructured":"Kong, G. et al. A two-decade population-based study on the effect of hypertension in the general population with obesity in the united States. Obes. (Silver Spring). 31, 832\u2013840. https:\/\/doi.org\/10.1002\/oby.23658 (2023).","journal-title":"Obes. (Silver Spring)"},{"key":"12583_CR54","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.eprac.2022.10.006","volume":"29","author":"VV Anand","year":"2023","unstructured":"Anand, V. V. et al. Barriers and facilitators to engagement with a weight management intervention in Asian patients with overweight or obesity: A systematic review. Endocr. Pract. 29, 398\u2013407. https:\/\/doi.org\/10.1016\/j.eprac.2022.10.006 (2023).","journal-title":"Endocr. Pract."},{"key":"12583_CR55","doi-asserted-by":"publisher","first-page":"942753","DOI":"10.3389\/fcvm.2022.942753","volume":"9","author":"CH Ng","year":"2022","unstructured":"Ng, C. H. et al. Hypertension is prevalent in non-alcoholic fatty liver disease and increases all-cause and cardiovascular mortality. Front. Cardiovasc. Med. 9, 942753. https:\/\/doi.org\/10.3389\/fcvm.2022.942753 (2022).","journal-title":"Front. Cardiovasc. Med."},{"key":"12583_CR56","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/S2468-1253(21)00020-0","volume":"6","author":"G Targher","year":"2021","unstructured":"Targher, G., Tilg, H. & Byrne, C. D. Non-alcoholic fatty liver disease: a multisystem disease requiring a multidisciplinary and holistic approach. Lancet Gastroenterol. Hepatol. 6, 578\u2013588. https:\/\/doi.org\/10.1016\/S2468-1253(21)00020-0 (2021).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"12583_CR57","doi-asserted-by":"publisher","first-page":"e015159","DOI":"10.1161\/CIRCIMAGING.122.015159","volume":"16","author":"B Chong","year":"2023","unstructured":"Chong, B. et al. Epicardial adipose tissue assessed by computed tomography and echocardiography are associated with adverse cardiovascular outcomes: A systematic review and Meta-Analysis. Circ. Cardiovasc. Imaging. 16, e015159. https:\/\/doi.org\/10.1161\/CIRCIMAGING.122.015159 (2023).","journal-title":"Circ. Cardiovasc. Imaging"},{"key":"12583_CR58","doi-asserted-by":"publisher","first-page":"971484","DOI":"10.3389\/fgene.2022.971484","volume":"13","author":"NWS Chew","year":"2022","unstructured":"Chew, N. W. S. et al. The genetic interactions between non-alcoholic fatty liver disease and cardiovascular diseases. Front. Genet. 13, 971484. https:\/\/doi.org\/10.3389\/fgene.2022.971484 (2022).","journal-title":"Front. Genet."},{"key":"12583_CR59","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1007\/s11883-022-01027-5","volume":"24","author":"NWS Chew","year":"2022","unstructured":"Chew, N. W. S., Ng, C. H., Muthiah, M. D. & Sanyal, A. J. Comprehensive review and updates on holistic approach towards Non-Alcoholic fatty liver disease management with cardiovascular disease. Curr. Atheroscler Rep. 24, 515\u2013532. https:\/\/doi.org\/10.1007\/s11883-022-01027-5 (2022).","journal-title":"Curr. Atheroscler Rep."},{"key":"12583_CR60","doi-asserted-by":"publisher","first-page":"643","DOI":"10.3892\/etm.2022.11580","volume":"24","author":"M Cao","year":"2022","unstructured":"Cao, M., Li, T., Li, Z., Gong, F. & Chen, Z. A retrospective study on the relationship between fibrosis\u20134 index and all\u2013cause mortality in patients with acute myocardial infarction. Exp. Ther. Med. 24, 643. https:\/\/doi.org\/10.3892\/etm.2022.11580 (2022).","journal-title":"Exp. Ther. Med."},{"key":"12583_CR61","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1177\/00033197231197230","volume":"75","author":"HM He","year":"2024","unstructured":"He, H. M. et al. A comparison of the prognostic value of liver fibrosis scores in acute myocardial infarction patients with and without type 2 diabetes. Angiology 75, 219\u2013230. https:\/\/doi.org\/10.1177\/00033197231197230 (2024).","journal-title":"Angiology"},{"key":"12583_CR62","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1007\/s00392-022-02078-z","volume":"112","author":"FG Biccire","year":"2023","unstructured":"Biccire, F. G. et al. Relationship between non-invasively detected liver fibrosis and in-hospital outcomes in patients with acute coronary syndrome undergoing PCI. Clin. Res. Cardiol. 112, 236\u2013246. https:\/\/doi.org\/10.1007\/s00392-022-02078-z (2023).","journal-title":"Clin. Res. Cardiol."},{"key":"12583_CR63","doi-asserted-by":"publisher","first-page":"e17622","DOI":"10.7759\/cureus.17622","volume":"13","author":"B Kumari","year":"2021","unstructured":"Kumari, B. et al. Diagnostic accuracy of FIB-4 and FIB-5 scores as compared to fibroscan for assessment of liver fibrosis in patients with Non-Alcoholic fatty liver disease. Cureus 13, e17622. https:\/\/doi.org\/10.7759\/cureus.17622 (2021).","journal-title":"Cureus"},{"key":"12583_CR64","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.jfma.2021.07.013","volume":"121","author":"XL Xu","year":"2022","unstructured":"Xu, X. L. et al. The role of fibrosis index FIB-4 in predicting liver fibrosis stage and clinical prognosis: A diagnostic or screening tool? J. Formos. Med. Assoc. 121, 454\u2013466. https:\/\/doi.org\/10.1016\/j.jfma.2021.07.013 (2022).","journal-title":"J. Formos. Med. Assoc."},{"key":"12583_CR65","doi-asserted-by":"publisher","first-page":"13616","DOI":"10.1038\/s41598-021-93038-6","volume":"11","author":"YH Roh","year":"2021","unstructured":"Roh, Y. H., Kang, B. K., Jun, D. W., Lee, C. M. & Kim, M. Role of FIB-4 for reassessment of hepatic fibrosis burden in referral center. Sci. Rep. 11, 13616. https:\/\/doi.org\/10.1038\/s41598-021-93038-6 (2021).","journal-title":"Sci. Rep."},{"key":"12583_CR66","doi-asserted-by":"crossref","unstructured":"Huttman, M. et al. Liver fibrosis stage based on the four factors (FIB-4) score or forns index in adults with chronic hepatitis C. Cochrane Database Syst. Rev. 8, CD011929 (2024).","DOI":"10.1002\/14651858.CD011929.pub2"},{"key":"12583_CR67","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1002\/hep.21669","volume":"46","author":"A Vallet-Pichard","year":"2007","unstructured":"Vallet-Pichard, A. et al. FIB\u20104: an inexpensive and accurate marker of fibrosis in HCV infection. Comparison with liver biopsy and fibrotest. Hepatology 46, 32\u201336 (2007).","journal-title":"Hepatology"},{"key":"12583_CR68","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1053\/j.gastro.2021.07.049","volume":"161","author":"F Kanwal","year":"2021","unstructured":"Kanwal, F. et al. Clinical care pathway for the risk stratification and management of patients with nonalcoholic fatty liver disease. Gastroenterology 161, 1657\u20131669 (2021).","journal-title":"Gastroenterology"},{"key":"12583_CR69","doi-asserted-by":"publisher","first-page":"13616","DOI":"10.1038\/s41598-021-93038-6","volume":"11","author":"YH Roh","year":"2021","unstructured":"Roh, Y. H., Kang, B. K., Jun, D. W., Lee, C. & Kim, M. Role of FIB-4 for reassessment of hepatic fibrosis burden in referral center. Sci. Rep. 11, 13616 (2021).","journal-title":"Sci. Rep."},{"key":"12583_CR70","doi-asserted-by":"publisher","first-page":"e031230","DOI":"10.1161\/JAHA.123.031230","volume":"12","author":"V Jain","year":"2023","unstructured":"Jain, V. et al. Immune activation mediates the association of advanced hepatic fibrosis with adverse outcomes in patients with coronary artery disease. J. Am. Heart Assoc. 12, e031230. https:\/\/doi.org\/10.1161\/JAHA.123.031230 (2023).","journal-title":"J. Am. Heart Assoc."},{"key":"12583_CR71","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1007\/s11886-023-01993-5","volume":"25","author":"TB Lee Jr","year":"2023","unstructured":"Lee, T. B. Jr. et al. Biomarkers of hepatic dysfunction and cardiovascular risk. Curr. Cardiol. Rep. 25, 1783\u20131795. https:\/\/doi.org\/10.1007\/s11886-023-01993-5 (2023).","journal-title":"Curr. Cardiol. Rep."},{"key":"12583_CR72","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.jhep.2013.08.011","volume":"60","author":"J Dyson","year":"2014","unstructured":"Dyson, J. et al. Hepatocellular cancer: the impact of obesity, type 2 diabetes and a multidisciplinary team. J. Hepatol. 60, 110\u2013117. https:\/\/doi.org\/10.1016\/j.jhep.2013.08.011 (2014).","journal-title":"J. Hepatol."},{"key":"12583_CR73","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1038\/ajg.2014.132","volume":"109","author":"G Zoppini","year":"2014","unstructured":"Zoppini, G. et al. Mortality from chronic liver diseases in diabetes. Am. J. Gastroenterol. 109, 1020\u20131025. https:\/\/doi.org\/10.1038\/ajg.2014.132 (2014).","journal-title":"Am. J. Gastroenterol."},{"key":"12583_CR74","doi-asserted-by":"publisher","first-page":"111652","DOI":"10.1016\/j.diabres.2024.111652","volume":"211","author":"NWS Chew","year":"2024","unstructured":"Chew, N. W. S. et al. Type 2 diabetes mellitus and cardiometabolic outcomes in metabolic dysfunction-associated steatotic liver disease population. Diabetes Res. Clin. Pract. 211, 111652. https:\/\/doi.org\/10.1016\/j.diabres.2024.111652 (2024).","journal-title":"Diabetes Res. Clin. Pract."},{"key":"12583_CR75","doi-asserted-by":"publisher","first-page":"16","DOI":"10.21037\/tgh-23-62","volume":"9","author":"J Singh","year":"2024","unstructured":"Singh, J. et al. Lower FIB-4 threshold in patients with diabetes improves diagnostic accuracy of the test in a Hispanic population. Transl Gastroenterol. Hepatol. 9, 16. https:\/\/doi.org\/10.21037\/tgh-23-62 (2024).","journal-title":"Transl Gastroenterol. Hepatol."},{"key":"12583_CR76","doi-asserted-by":"publisher","unstructured":"Vigano, M. et al. Accuracy of FIB-4 to detect elevated liver stiffness measurements in patients with Non-Alcoholic fatty liver disease: A Cross-Sectional study in referral centers. Int. J. Mol. Sci. 23 https:\/\/doi.org\/10.3390\/ijms232012489 (2022).","DOI":"10.3390\/ijms232012489"},{"key":"12583_CR77","doi-asserted-by":"publisher","first-page":"100780","DOI":"10.1016\/j.lanepe.2023.100780","volume":"36","author":"QM Anstee","year":"2024","unstructured":"Anstee, Q. M. et al. Prognostic utility of Fibrosis-4 index for risk of subsequent liver and cardiovascular events, and all-cause mortality in individuals with obesity and\/or type 2 diabetes: a longitudinal cohort study. Lancet Reg. Health Eur. 36, 100780. https:\/\/doi.org\/10.1016\/j.lanepe.2023.100780 (2024).","journal-title":"Lancet Reg. Health Eur."},{"key":"12583_CR78","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.bbacli.2014.09.001","volume":"3","author":"GB Goh","year":"2015","unstructured":"Goh, G. B. et al. Clinical spectrum of non-alcoholic fatty liver disease in diabetic and non-diabetic patients. BBA Clin. 3, 141\u2013145. https:\/\/doi.org\/10.1016\/j.bbacli.2014.09.001 (2015).","journal-title":"BBA Clin."},{"key":"12583_CR79","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1007\/s00535-012-0704-y","volume":"48","author":"M Yoneda","year":"2013","unstructured":"Yoneda, M. et al. Noninvasive scoring systems in patients with nonalcoholic fatty liver disease with normal Alanine aminotransferase levels. J. Gastroenterol. 48, 1051\u20131060. https:\/\/doi.org\/10.1007\/s00535-012-0704-y (2013).","journal-title":"J. Gastroenterol."},{"key":"12583_CR80","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.amjcard.2023.02.023","volume":"196","author":"C Lin","year":"2023","unstructured":"Lin, C. et al. Mortality, cardiovascular, and medication outcomes in patients with myocardial infarction and underweight in a Meta-Analysis of 6.3 million patients. Am. J. Cardiol. 196, 1\u201310. https:\/\/doi.org\/10.1016\/j.amjcard.2023.02.023 (2023).","journal-title":"Am. J. Cardiol."},{"key":"12583_CR81","doi-asserted-by":"publisher","first-page":"101685","DOI":"10.1016\/j.eclinm.2022.101685","volume":"54","author":"YH Chin","year":"2022","unstructured":"Chin, Y. H. et al. The placebo response rate and Nocebo events in obesity Pharmacological trials. A systematic review and meta-analysis. EClinicalMedicine 54, 101685. https:\/\/doi.org\/10.1016\/j.eclinm.2022.101685 (2022).","journal-title":"EClinicalMedicine"},{"key":"12583_CR82","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1093\/ehjqcco\/qcac060","volume":"9","author":"YH Chin","year":"2023","unstructured":"Chin, Y. H. et al. Meta-analysis of the placebo and Nocebo effects associated with placebo treatment in randomized trials of lipid-lowering therapies. Eur. Heart J. Qual. Care Clin. Outcomes. 9, 511\u2013519. https:\/\/doi.org\/10.1093\/ehjqcco\/qcac060 (2023).","journal-title":"Eur. Heart J. Qual. Care Clin. Outcomes"},{"key":"12583_CR83","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1002\/oby.24002","volume":"32","author":"XH Pan","year":"2024","unstructured":"Pan, X. H. et al. Efficacy and safety of tirzepatide, GLP-1 receptor agonists, and other weight loss drugs in overweight and obesity: a network meta-analysis. Obes. (Silver Spring). 32, 840\u2013856. https:\/\/doi.org\/10.1002\/oby.24002 (2024).","journal-title":"Obes. (Silver Spring)"},{"key":"12583_CR84","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1093\/nutrit\/nuad163","volume":"82","author":"HSJ Chew","year":"2024","unstructured":"Chew, H. S. J. et al. Anthropometric and cardiometabolic effects of polyphenols in people with overweight and obesity: an umbrella review. Nutr. Rev. 82, 1556\u20131593. https:\/\/doi.org\/10.1093\/nutrit\/nuad163 (2024).","journal-title":"Nutr. Rev."},{"key":"12583_CR85","doi-asserted-by":"publisher","DOI":"10.1007\/s00392-024-02563-7","author":"VV Anand","year":"2024","unstructured":"Anand, V. V. et al. Sex differences in survival following acute coronary syndrome with and without standard modifiable risk factors. Clin. Res. Cardiol. https:\/\/doi.org\/10.1007\/s00392-024-02563-7 (2024).","journal-title":"Clin. Res. Cardiol."},{"key":"12583_CR86","doi-asserted-by":"publisher","first-page":"100067","DOI":"10.1016\/j.jhepr.2020.100067","volume":"2","author":"K Patel","year":"2020","unstructured":"Patel, K. & Sebastiani, G. Limitations of non-invasive tests for assessment of liver fibrosis. JHEP Rep. 2, 100067. https:\/\/doi.org\/10.1016\/j.jhepr.2020.100067 (2020).","journal-title":"JHEP Rep."},{"key":"12583_CR87","doi-asserted-by":"publisher","unstructured":"Canivet, C. M. & Boursier, J. Screening for liver fibrosis in the general population: where do we stand in 2022? Diagnostics (Basel). 13. https:\/\/doi.org\/10.3390\/diagnostics13010091 (2022).","DOI":"10.3390\/diagnostics13010091"},{"key":"12583_CR88","first-page":"17","volume":"3","author":"S Gowda","year":"2009","unstructured":"Gowda, S. et al. A review on laboratory liver function tests. Pan Afr. Med. J. 3, 17 (2009).","journal-title":"Pan Afr. Med. J."},{"key":"12583_CR89","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/S2468-1253(19)30349-8","volume":"5","author":"GBDC Collaborators","year":"2020","unstructured":"Collaborators, G. B. D. C. The global, regional, and National burden of cirrhosis by cause in 195 countries and territories, 1990\u20132017: a systematic analysis for the global burden of disease study 2017. Lancet Gastroenterol. Hepatol. 5, 245\u2013266. https:\/\/doi.org\/10.1016\/S2468-1253(19)30349-8 (2020).","journal-title":"Lancet Gastroenterol. Hepatol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-12583-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-12583-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-12583-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T16:53:46Z","timestamp":1757264026000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-12583-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,21]]},"references-count":89,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["12583"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-12583-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,21]]},"assertion":[{"value":"26 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was approved by the local institutional review committee in accordance with the revised Declaration of Helsinki (NHG Research\u2014DSRB: 2021\/00089-AMD0001). The institutional review board waived the need for written patient consent as this study involved a retrospective analysis of clinically acquired data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"26499"}}